97191 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
Anti-GITR antigen-binding proteins and methods of use thereof
#602Monoclonal anti-CD95L antibody
#603Anti-OX40 antibodies and their uses
#604COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN
#605CD40L binding polypeptide
#606Anti-CD154 antibody having improved binding, functional and safety characteristics
#607Nucleic acids encoding antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease
#608Anti-OX40 antibodies and their uses
#609SINGLE VARIABLE DOMAIN ANTIBODIES AGAINST OX40L, CONSTRUCTS AND THERAPEUTIC USE
#610Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF
#611Anti-BAFF antibodies
#612Anti-Dkk-1-anti-RANKL bispecific antibody compounds
#613SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#614HOMOGENEOUS ANTIBODY POPULATIONS
#615METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BONE METASTASES
#616ANTIBODIES THAT BIND TO TL1A AND THEIR USES
#617Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#618Antibody-drug conjugate produced by binding through linker having hydrophilic structure
#619RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS
#620TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#621Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L
#622Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
#623Antibodies conjugatable by transglutaminase and conjugates made therefrom
#624Antigen binding complex having agonistic activity and methods of use
#625TREATMENT OF AUTOIMMUNE DISORDERS WITH CD154 ANTIBODIES
#626Affinity chromatography wash buffer
#627Anti-NGF antibodies and anti-NGF antibody fragments
#628Methods of immune therapy with anti-CD154 antibodies having Fc modifications
#629Method for the prognosis and treatment of cancer metastasis
#630Anti APRIL (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
#631Antibodies to CD70
#632SELF-BUFFERING PROTEIN FORMULATIONS
#633COMPOSITIONS AND METHODS FOR MODULATING SALM5 AND HVEM
#634MULTISPECIFIC ANTIBODIES
#635Antagonistic anti-OX40L antibodies and methods of their use
#636TOLEROGENIC COMPOSITIONS AND METHODS
#637Anti-CD40L antibodies
#638Humanized Anti-CD70 Binding Agents and Uses Thereof
#639Bacterial host strain expressing recombinant DSBC
#640Methods of treating comprising administering anti-OX40L antibodies
#641Synergistic combinations of OX40L antibodies for the treatment of GvHD
#642Anti-NGF compositions and use thereof
#643ANTI-LIGHT ANTIBODIES
#644RANKL-specific agent for treating metastatic disease
#645METHODS OF TREATING AUTOIMMUNE DISEASE USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L
#646Pyrrolobenzodiazepines and targeted conjugates
#647Anti-LIGHT antibodies
#648Methods of treating pain with compositions comprising RANK/RANKL antagonists and related compounds
#649Serum albumin binding proteins containing immunoglobulin single variable domains
#650Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#651Production of proteins in labyrinthulomycetes
#652CD27L antigen binding proteins
#653Synergistic combinations of OX40L antibodies for the treatment of GvHD
#654BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#655TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA
#656T-cell redirecting bispecific antibodies for treatment of disease
#657TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES
#658COMPOSITIONS AND METHODS FOR TREATING B CELL MEDIATED AUTOIMMUNE DISORDERS
#659Stable IGG4 based binding agent formulations
#660Bispecific T cell engaging antibody constructs
#661METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE
#662DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE
#663Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
#664ANTI-DEATH RECEPTOR 3 (DR3) ANTAGONISTIC ANTIBODIES WITH REDUCED AGONISTIC ACTIVITY
#665ANTIBODIES TO OPGL
#666Methods and systems for predicting response to immunotherapies for treatment of cancer
#667METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE
#668Recombinant AAV vectors useful for reducing immunity against transgene products
#669INHIBITORS OF THE CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS
#670Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
#671Anti-inflammatory molecules with tissue-targeting functions
#672Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells
#673Serum half-life extension using IgBD
#674Methods of preventing inflammation and treating pain using anti-NGF compositions
#675MULTISPECIFIC ANTIBODIES
#676Antibody constructs for CD70 and CD3
#677Immunoglobulin variable domains
#678Method for the Prognosis and Treatment of Cancer Metastasis
#679HUMAN ANTIBODIES TO HUMAN TNF-LIKE LIGAND 1A (TL1A)
#680AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS
#681Anti-Blys antibody formulations and methods of treatment using them
#682Method for the production of domain antibodies
#683Antibodies that specifically bind to TL1A
#684Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV
#685Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
#686Proteins specific for BAFF and B7RP1
#687LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT
#688Pharmaceuticals in joint-linker configurations for treating pathological blood clots
#689METHODS OF TREATING TRANSPLANT REJECTION USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40
#690Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75
#691Diagnostic anti-CD95L antibody
#692Methods of treating SLE with anti-OX40L antibodies
#693SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
#694Anti-CD154 antibodies and methods of using them
#695Methods and Compositions for Treating Conditions of the Eye
#696LIPOTEICHOIC ACID FROM LACTOBACILLI AS A POTENT IMMUNE STIMULATORY ADJUVANT FOR VACCINE DEVELOPMENT
#697Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
#698Methods using RANK/RANKL antagonist antibodies for treating pain
#699Humanized anti-CD70 binding agents and uses thereof
#700T-cell redirecting bispecific antibodies for treatment of disease
#701CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS
#702Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
#703Anti-hOX40L antibodies, uses, and methods
#704Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
#705Hybrid constant regions
#706Anti-OX40L antibodies and methods of treating graft versus host disease
#707Variant target binding agents and uses thereof
#708Immunomodulatory compositions
#709Anti-OX40 antibodies
#710Optimized Fc variants and methods for their generation
#711Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
#712Methods and monitoring of treatment with a WNT pathway inhibitor
#713SELF-BUFFERING PROTEIN FORMULATIONS
#714Multivalent antibodies
#715Antibodies against TL1a and uses thereof
#716Baff selective binding compounds and related methods
#717Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#718Anti-human RANKL antibody, humanized antibody of the same, and pharmaceutical composition and use thereof
#719Optimized Fc variants and methods for their generation
#720USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO PROMOTE TRANSPLANTATION TOLERANCE
#721Drug for preventing, treating or preventing metastasis of giant cell tumor that occurs in bone or soft parts, chondrosarcoma, or osteosarcoma, local injection for arterial embolization, and artificial bone
#722Methods for treating cancer
#723Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
#724Pyrrolobenzodiazepines and targeted conjugates
#725Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#726ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#727Antibody-drug conjugate
#728STABLE FORMULATIONS OF POLYPEPTIDES AND USES THEREOF
#729Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
#730Synergistic combinations of OX40L antibodies for the treatment of GVHD
#731Altered APRIL binding antibodies
#732Anti-BAFF-anti-IL-17 bispecific antibodies
#733TWEAK ANTAGONISTS FOR TREATING LUPUS NEPHRITIS AND MUSCLE ATROPHY
#734Anti-EGFR activatable antibodies
#735ANDROGEN RECEPTOR MODULATOR AND USES THEREOF
#736Human immune therapies using a CD27 agonist in combination with another immune agonist to treat cancer
#737Molecular constructs with targeting and effector moieties
#738Peptide core-based multi-arm linkers
#739Molecular constructs for treating tumors
#740Proliferation-inducing ligand (APRIL)-binding peptides
#741BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
#742CD70-BINDING PEPTIDES AND METHOD, PROCESS AND USE RELATING THERETO
#743Antibody locker for the inactivation of protein drug
#744T-cell redirecting bispecific antibodies for treatment of disease
#745Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
#746ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
#747Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
#748CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis
#749METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS
#750Targeted pyrrolobenzodiazapine conjugates
#751Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
#752Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
#753Methods of reducing skeletal muscle loss using an antibody against Fn14
#754Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and HLA-E-bearing composition
#755Antagonist of the BTLA/HVEM interaction for use in therapy
#756Treatment of complex regional pain syndrome using denosumab
#757Antibody polypeptides that antagonize CD40L
#758Anti-ectodysplasin antibodies
#759Sequence dependent aggregation
#760Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#761Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
#762Human CD30 ligand antigen binding proteins
#763Anti-RANKL antibodies and methods of use
#764Hybrid immunoglobulin containing non-peptidyl linkage
#765Proteins specific for BAFF and B7RP1 and uses thereof
#766Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
#767Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#768Detection and Treatment of Pancreatic, Ovarian and Other CD70 Positive Cancers
#769BLOOD-BRAIN BARRIER (BBB) PENETRATING DUAL SPECIFIC BINDING PROTEINS FOR TREATING BRAIN AND NEUROLOGICAL DISEASES
#770Carbohydrate phosphonate derivatives as modulators of glycosylation
#771Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75
#772Composition comprising a TNFR agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma
#773Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
#774Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
#775Antibody-drug conjugate produced by binding through linker having hydrophilic structure
#776Antagonistic human light-specific human monoclonal antibodies
#777Methods of preventing or treating pain using anti-NGF antibodies
#778USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO PROMOTE TRANSPLANTATION TOLERANCE
#779METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BONE METASTASES
#780Antibody-drug conjugate
#781Method for the prognosis and treatment of cancer metastasis
#782Antibody constant region variant
#783Antibodies to CD70
#784Anti-BLyS antibody
#785Methods related to denosumab
#786Modulation of activity of neurotrophins
#787CD27L antigen binding proteins
#788Single variable domain antibodies against OX40L, constructs and therapeutic use
#789Anti-BAFF antibodies
#790Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
#791Inhibitors of the CD95 signaling pathway for treatment of MDS
#792Method for the diagnosis, prognosis and treatment of lung cancer metastasis
#793Anti-CD70 antibody drug conjugates
#794Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
#795Bispecific antibodies against human TWEAK and human IL17 and uses thereof
#796Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
#797Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with type B peptide
#798THERAPEUTIC STRATEGY FOR TREATING AUTOIMMUNE AND DEGENERATIVE DISEASES
#799Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
#800CD40L-specific TN3-derived scaffolds and methods of use thereof
#801FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS
#802Optimized Fc variants and methods for their generation
#803Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof
#804Antibody polypeptides that antagonize CD40L
#805Binding molecules for BCMA and CD3
#806AGLYCOSYL ANTI-CD154 (CD40 LIGAND) ANTIBODIES AND USES THEREOF
#807PULMONARY HYPERTENSION
#808FC VARIANTS
#809Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
#810Binding molecules for BCMA and CD3
#811Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#812Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#813Humanized antibodies against TL1A
#814Antibodies that bind to TL1A and their uses
#815Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
#816Chimeric human-llama antigens and methods of use
#817Methods of evaluating BAFF
#818Pulmonary hypertension
#819ANTIBODIES AGAINST TL1a AND USES THEREOF
#820Antibodies to CD70
#821Anti-CD154 antibodies
#822Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
#823TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#824Humanized anti-CD70 binding agents and uses thereof
#825Stable formulations of polypeptides and uses thereof
#826Antibodies to CD70
#827Bacterial host strain expressing recombinant DSBC
#828Antibodies to CD70
#829ANTIBODIES TO OPGL
#830Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A
#831Variant target binding agents and uses thereof
#832Nucleic acids encoding antibody polypeptides that antagonize CD40L
#833Anti-CD40 antibodies and methods of administering thereof
#834Linker peptides and polypeptides comprising same
#835T-cell redirecting bispecific antibodies for treatment of disease
#836ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE
#837Methods of preventing or treating pain using anti-NGF antibodies
#838Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
#839Stable IgG4 based binding agent formulations
#840Methods of preventing inflammation and treating pain using anti-NGF compositions
#841Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
#842Anti-NGF compositions and use thereof
#843HUMANIZED ANTIBODIES AGAINST LIGHT AND USES THEREOF
#844ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL)
#845Method for the treatment of neurodegenerative diseases
#846Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#847Anti-BAFF-anti-IL-17 bispecific antibodies
#848Self-buffering antibody formulations
#849Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof
#850Optimized Fc variants and methods for their generation
#851Antagonistic human light-specific human monoclonal antibodies
#852Methods for treating TWEAK-related conditions
#853Carrier immunoglobulins and uses thereof
#854Binding molecules for BCMA and CD3
#855Binding molecules for BCMA and CD3
#856Optimized Fc variants and methods for their generation
#857Optimized FC variants and methods for their generation
#858Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#859Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#860Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
#861Antibody polypeptides that antagonize CD40L
#862CD27L antigen binding proteins
#863Sequence dependent aggregation
#864Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof
#865Seizure and Migraine Treatments using Denosumab
#866Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
#867Targeted pyrrolobenzodiazapine conjugates
#868TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
#869METHODS FOR REDUCING THE LEVEL OF ALLOANTIBODIES IN A SUBJECT
#870Single variable domain antibodies against OX40L, constructs and therapeutic use
#871METHODS OF IDENTIFYING OBM MODULATORS
#872Compositions and Methods for Treating Inflammatory Lung Disease
#873Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
#874Humanized antibodies against TL1A
#875Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
#876Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
#877Multivalent Antibodies
#878Viral chemokine-antigen fusion proteins
#879METHODS AND COMPOSITIONS FOR MODULATING TWEAK AND FN14 ACTIVITY
#880Methods of reducing inflammation in cardiomyopathy
#881Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
#882Dual Variable Domain Immunoglobulins and Uses Thereof
#883Treatment of B-cell cancers with anti-CD70 antibody-drug conjugates
#884STABILIZED SINGLE DOMAIN ANTIBODIES
#885USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS
#886Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine
#887Methods of evaluating BAFF
#888Optimized Fc variants and methods for their generation
#889Seizure and Migraine Treatments using the Bone Homeostasis Drug Cinacalcet
#890METHODS OF TARGETING BAFF
#891Modified antibody compositions, methods of making and using thereof
#892Antibodies against human tweak and uses thereof
#893SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#894APRIL ANTAGONISTS AND METHODS OF USE
#895Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof
#896METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES
#897Receptor activator of NF-kappaB
#898Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
#899Method for the production of domain antibodies
#900Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors